TransCon PTH

COMBINATION_PRODUCT4 trials

Sponsors

Ascendis Pharma Bone Diseases A/S, Ascendis Pharma A/S, Visen Pharmaceuticals (Shanghai) Co., Ltd.

Conditions

Endocrine System DiseasesHypoparathyroidismHypoparathyroidism (HP) in AdultsParathyroid DiseasesParathyroid Hormone Deficiency

Phase 2

A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism

CompletedNCT04009291

Ascendis Pharma A/SEndocrine System Diseases, Hypoparathyroidism, Parathyroid Diseases

Start: 2019-08-27End: 2025-04-17Updated: 2026-06-18

PaTH Forward: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group Trial with an Open-Label Extension, Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Subcutaneously Daily in Adults with Hypoparathyroidism

CompletedCTIS2024-512967-29-00

Ascendis Pharma Bone Diseases A/SHypoparathyroidism (HP) in Adults

Start: 2019-09-03End: 2025-03-21Target: 21Updated: 2024-11-19

Phase 3

A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Daily in Adults With Hypoparathyroidism

CompletedNCT04701203

Ascendis Pharma Bone Diseases A/SEndocrine System Diseases, Hypoparathyroidism, Parathyroid Diseases

Start: 2021-02-16End: 2025-01-21Updated: 2026-07-07

PaTHway CHINA TRIAL: A Trial to Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism

CompletedNCT05387070

Visen Pharmaceuticals (Shanghai) Co., Ltd.Endocrine System Diseases, Hypoparathyroidism, Parathyroid Diseases +1

Start: 2021-07-28End: 2026-01-08Updated: 2026-01-16

Related Papers

Measuring treatment impacts on symptoms in adults with hypoparathyroidism: findings from the PaTHway trial.

2024-08-13

Palopegteriparatide Treatment Improves Renal Function in Adults with Chronic Hypoparathyroidism: 1-Year Results from the Phase 3 PaTHway Trial.

2024-04-3018 citations